<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CRISPR gene-editing &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/crispr-gene-editing/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 26 Jan 2026 02:46:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>CRISPR gene-editing &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Enhancing CAR-T Cells: Targeting Tumor Characteristics</title>
		<link>https://bioengineer.org/enhancing-car-t-cells-targeting-tumor-characteristics/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 26 Jan 2026 02:45:49 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[and overcoming limitations]]></category>
		<category><![CDATA[and personalized approaches]]></category>
		<category><![CDATA[Based on the content focusing on next-gen CAR-T cells targeting tumor-specific features]]></category>
		<category><![CDATA[Based on the content focusing on next-generation CAR-T cell design]]></category>
		<category><![CDATA[Combination cancer therapies]]></category>
		<category><![CDATA[combination immunotherapy]]></category>
		<category><![CDATA[CRISPR gene-editing]]></category>
		<category><![CDATA[here are 5 appropriate tags: **Next-generation CAR-T]]></category>
		<category><![CDATA[here are 5 suitable tags: **Next-generation CAR-T cells]]></category>
		<category><![CDATA[microenvironment adaptation]]></category>
		<category><![CDATA[personalized cancer immunotherapy]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tumor microenvironment targeting]]></category>
		<category><![CDATA[tumor targeting]]></category>
		<guid isPermaLink="false">https://bioengineer.org/enhancing-car-t-cells-targeting-tumor-characteristics/</guid>

					<description><![CDATA[In a groundbreaking advancement in cancer immunotherapy, researchers have unveiled the next-generation design of CAR-T cells that strategically leverage unique tumor features to enhance therapeutic efficacy. This innovative approach promises to significantly improve patient outcomes in the ongoing battle against resilient malignancies. By capitalizing on tumor heterogeneity and microenvironmental cues, this study paves the way [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320878</post-id>	</item>
		<item>
		<title>From Bloodstream to Solid Tumors: A Breakthrough Boost for CAR T Cell Therapy</title>
		<link>https://bioengineer.org/from-bloodstream-to-solid-tumors-a-breakthrough-boost-for-car-t-cell-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 03 Nov 2025 18:26:00 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAR T cell therapy for solid tumors]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[CRISPR gene editing advancements]]></category>
		<category><![CDATA[CRISPR gene-editing]]></category>
		<category><![CDATA[Immune checkpoint inhibitors]]></category>
		<category><![CDATA[Intracellular immune checkpoint targeting]]></category>
		<category><![CDATA[PTPN2 inhibition]]></category>
		<category><![CDATA[PTPN2 inhibition in immunotherapy]]></category>
		<category><![CDATA[solid tumor immunotherapy]]></category>
		<category><![CDATA[T cell memory enhancement]]></category>
		<guid isPermaLink="false">https://bioengineer.org/from-bloodstream-to-solid-tumors-a-breakthrough-boost-for-car-t-cell-therapy/</guid>

					<description><![CDATA[Chimeric Antigen Receptor (CAR) T cell therapies have heralded a new era in oncological treatment, yielding transformative outcomes particularly in hematologic malignancies. These immunotherapies engineer patients’ own T cells to express synthetic receptors that selectively recognize and eradicate cancerous cells in the bloodstream. However, despite their spectacular success against blood cancers, CAR T cells have [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">290665</post-id>	</item>
		<item>
		<title>Enhancing the Body’s Natural Defenses Against Cancer</title>
		<link>https://bioengineer.org/enhancing-the-bodys-natural-defenses-against-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 24 Sep 2025 16:32:59 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[CRISPR gene-editing]]></category>
		<category><![CDATA[Genetic engineering]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/enhancing-the-bodys-natural-defenses-against-cancer/</guid>

					<description><![CDATA[In a groundbreaking advancement in the field of cancer treatment, researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Medical University of Vienna have introduced a highly innovative platform designed to enhance the efficacy of CAR T cell therapy. This development addresses the limitations associated with traditional [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">271812</post-id>	</item>
		<item>
		<title>Genetic Screening Advances Boost CAR-T Therapy Effectiveness Against Multiple Myeloma and Other Cancers</title>
		<link>https://bioengineer.org/genetic-screening-advances-boost-car-t-therapy-effectiveness-against-multiple-myeloma-and-other-cancers/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 24 Sep 2025 15:42:46 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[CRISPR gene-editing]]></category>
		<category><![CDATA[in vivo CRISPR screening]]></category>
		<category><![CDATA[multiple myeloma]]></category>
		<guid isPermaLink="false">https://bioengineer.org/genetic-screening-advances-boost-car-t-therapy-effectiveness-against-multiple-myeloma-and-other-cancers/</guid>

					<description><![CDATA[In a groundbreaking advance that could redefine the future of cancer immunotherapy, researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have harnessed the power of CRISPR gene-editing technology to optimize chimeric antigen receptor (CAR)-T cell therapies against multiple myeloma. This innovative study, recently published in Nature, unveils how systematic genetic [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">271783</post-id>	</item>
	</channel>
</rss>
